Ganaplacide + Itraconazole
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria
Trial Timeline
Nov 18, 2021 โ May 14, 2022
NCT ID
NCT05084651About Ganaplacide + Itraconazole
Ganaplacide + Itraconazole is a phase 1 stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT05084651. Target conditions include Malaria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05084651 | Phase 1 | Completed |
Competing Products
20 competing products in Malaria